• This record comes from PubMed

Expression, Epigenetic and Genetic Changes of HNF1B in Endometrial Lesions

. 2016 Jul ; 22 (3) : 523-30. [epub] 20151219

Language English Country Switzerland Media print-electronic

Document type Journal Article

Persistent link   https://www.medvik.cz/link/pmid26685938
Links

PubMed 26685938
DOI 10.1007/s12253-015-0037-2
PII: 10.1007/s12253-015-0037-2
Knihovny.cz E-resources

Hepatocyte nuclear factor 1-beta (HNF-1-beta) is a transcription factor involved in cancerogenesis of various tumors, including endometrioid carcinoma. We performed comprehensive analysis of HNF-1-beta in lesions of the endometrium, including protein expression and genetic and epigenetic changes. Expression of HNF-1-beta was analyzed immunohistochemically in 320 cases including both tumor and non-tumor endometrial lesions. Promoter methylation and genetic variants were evaluated, using bisulphite and direct sequencing, in 30 (18 fresh frozen, 12 FFPE tumors) endometrioid carcinomas (ECs) and 15 ovarian clear cell carcinomas (OCCCs) as a control group. We detected expression of HNF-1-beta in 28 % of ECs (51/180 cases), 26 % of serous carcinoma (7/27 cases), 83 % of endometrial clear cell carcinoma (15/18 cases), 93 % of hyperplastic polyps with atypias (13/14 cases), 100 % of hyperplastic polyps without atypias (16/16 cases), 88 % of hyperplasias with atypias (14/16 cases), 91 % of hyperplasias without atypias (10/11 cases), and in ≥80 % of different normal endometrium samples. The control group of OCCCs showed HNF-1-beta expression in 95 % (18/19 cases). Methylation in promoter region was detected in 13.3 % (4/30) of ECs, but not in corresponding normal tissue where available, nor in OCCCs (0/15 cases). Mutation analysis revealed truncating variant c.454C > T (p.Gln152X) in one EC and missense variant c.848C > T (p.Ala283Val) was detected in one OCCC. In conclusion, expression of HNF-1-beta was detected in various extents in all types of lesions analyzed, nevertheless its strong expression was mostly limited to clear cell carcinomas. Biological significance of genetic and epigenetic changes needs further investigation.

See more in PubMed

Lab Invest. 2015 Aug;95(8):962-72 PubMed

Mod Pathol. 2011 Apr;24(4):512-21 PubMed

Am J Pathol. 2003 Dec;163(6):2503-12 PubMed

FASEB J. 1996 Feb;10(2):267-82 PubMed

Nat Genet. 2011 May;43(5):451-4 PubMed

Pathology. 2015 Feb;47(2):105-11 PubMed

Hum Pathol. 2007 Jul;38(7):1074-80 PubMed

J Am Soc Nephrol. 2000 Nov;11 Suppl 16:S140-3 PubMed

Am J Surg Pathol. 2015 Aug;39(8):1061-9 PubMed

Hum Mol Genet. 2015 Mar 1;24(5):1478-92 PubMed

Mod Pathol. 2008 Sep;21(9):1075-83 PubMed

Nucleic Acids Res. 2011 Jan;39(Database issue):D945-50 PubMed

Hum Mol Genet. 2004 Dec 15;13(24):3139-49 PubMed

Ann Intern Med. 2004 Apr 6;140(7):510-7 PubMed

Virchows Arch. 2008 Feb;452(2):175-80 PubMed

Nat Genet. 2013 Apr;45(4):362-70, 370e1-2 PubMed

Am J Surg Pathol. 2015 Aug;39(8):1148-55 PubMed

Mod Pathol. 2006 Jan;19(1):83-9 PubMed

Urology. 2010 Aug;76(2):507.e6-11 PubMed

Histol Histopathol. 2009 Nov;24(11):1479-86 PubMed

Appl Immunohistochem Mol Morphol. 2012 Dec;20(6):580-7 PubMed

Hum Mol Genet. 2005 Mar 1;14(5):603-14 PubMed

Nat Genet. 1997 Dec;17(4):384-5 PubMed

EMBO J. 1993 Nov;12(11):4229-42 PubMed

BMC Cancer. 2015 Apr 07;15:229 PubMed

Am J Surg Pathol. 2012 Jun;36(6):799-807 PubMed

BMC Cancer. 2010 Jun 22;10:315 PubMed

Br J Cancer. 2006 Mar 27;94(6):914-21 PubMed

Diagn Pathol. 2015 Mar 25;10:8 PubMed

Development. 2008 Aug;135(16):2777-86 PubMed

Neoplasia. 2008 Dec;10 (12 ):1481-92, 3p following 1492 PubMed

Histopathology. 2014 Mar;64(4):585-96 PubMed

J Diabetes Complications. 2010 Sep-Oct;24(5):345-53 PubMed

Nat Commun. 2013;4:1628 PubMed

Am J Surg Pathol. 2011 May;35(5):633-46 PubMed

Find record

Citation metrics

Archiving options